Developing personalized cancer immunotherapies using microfluidics
Official title: Using microfluidics to realize patient-specific anti-cancer immunotherapies
Funded at Stanford University · NIH-10931361 · Data updated 2026-11-12
This study is exploring a new way to make cancer treatments more effective by using special technology to create personalized therapies that help your immune cells, called T cells, better fight your cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project start | September 19, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $1,080,800 |
| NIH project number | 5DP1CA290563-02 |
| Project ID | NIH-10931361 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with various types of cancer who are seeking personalized treatment options.
✕Less likely to help
Patients with non-cancerous conditions or those who do not have a suitable immune response may not benefit from this research.
What this research studies
This research focuses on enhancing cancer treatment by utilizing microfluidic technology to create patient-specific immunotherapies. It aims to improve the activation of T cells, which are crucial for targeting and destroying cancer cells. By analyzing the interactions between T cell receptors and cancer-specific antigens, the research seeks to identify the most effective combinations for each patient. This personalized approach could lead to more effective and tailored cancer treatments.
Why it matters
Potential benefit: If successful, this research could provide patients with more effective and personalized cancer immunotherapies that specifically target their unique cancer profiles.
How similar studies have gone: Previous research has shown promise in using personalized immunotherapies for cancer treatment, indicating that this approach could lead to significant advancements.
Where this research is happening
-
Stanford University
Stanford, United States Active
Researchers
- Principal investigator: Fordyce, Polly Morrell — Stanford University
- Study coordinator: Fordyce, Polly Morrell
Related research
Other NIH-funded projects on the same topics.
-
Multimodal AI to predict CAR-T patient response and guide safer, smarter cell design
A Stanford team is building AI tools that use patient and CAR-T cell data to predict how well a CAR-T therapy will work and what design changes might boost effectiveness and safety for people with cancer.
-
Community-driven model to reduce overdose deaths through smarter resource use
A Stanford-led project uses a data-driven model to help counties pick the best ways to prevent opioid and stimulant overdoses and save lives.
-
Center for Dissemination and Implementation at Stanford: Research Core
A Stanford-based program is advancing how evidence-based addiction treatments are implemented across settings to help people with substance use disorders receive better care.
-
Center for Dissemination and Implementation At Stanford (C-DIAS)
A center-based program at Stanford aims to speed people who need addiction treatments to get evidence-based care.
-
Mitochondrial structure and neuron health in Alzheimer's and ALS
This grant studies how mitochondrial cristae structure in neurons is controlled and how its disruption may contribute to diseases like Alzheimer's and ALS.
-
Pediatric EMS seizures: simpler age-based midazolam dosing
A nationwide trial at EMS agencies tests whether using fixed, age-based dosing of midazolam for seizures in children improves treatment speed and safety.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.